Timex Group promoter to sell 4.47% stake via OFS at ₹275 per share
Timex Group Luxury Watches BV will sell a 4.47 percent stake in Timex Group India via OFS on December 29 and 30, with Kotak Securities…
Latest News
Vikran Engineering secures 45.75 MW solar projects in Madhya Pradesh
Vikran Engineering Ltd accepted awards from MP Urja Vikas Nigam Ltd to set up 45.75 MW solar projects in Vidisha under PM-KUSUM, selling power to…
IFSCA says GIFT City bond market remains institution-led, retail access to evolve over time
IFSCA chairman K Rajaraman said the GIFT City bond market is primarily institutional, with Indian corporates raising offshore debt through NSE IX and India INX.…
Titan bets on lab-grown diamonds with ‘beYon’ to tap new jewellery buyers
Titan’s move into lab-grown diamonds marks a cautious but strategic diversification, with the Tata Group company positioning the ‘beYon’ brand as an affordable, lifestyle-led offering…
GE Shipping signs pact to sell very large gas carrier ‘Jag Vishnu’
The Great Eastern Shipping Company Ltd will sell its gas carrier Jag Vishnu and Kamsarmax Jag Aarati, and acquire two second-hand vessels, aiming to optimise…
Coal India board appoints B Sairam as chief executive officer
Coal India Ltd appoints B Sairam as CEO, consolidating leadership. Sairam, with over 30 years in coal, previously led Northern Coalfields Ltd and Central Coalfields…
Economists see consumption-led growth in FY27, rupee in a 90-93 range
Post Content
Nifty ends three-week losing streak, but IT and auto stocks drag
Benchmark indices ended the week with modest gains, snapping a three-week losing streak, while Friday saw Nifty slip below 26,050, dragged lower by IT and…
Value emerging in beaten-down railway, PSU stocks: Spark Private Wealth’s Devang Mehta
Devang Mehta, Deputy Managing Director and Chief Investment Officer–Equity (NDPMS) at Spark Private Wealth Management, said the investment case for railway and PSU companies has…
Sun Pharma eyes mid-high single digit revenue growth in FY26, bets on innovation
Sun Pharmaceutical Industries targets mid- to high-single digit topline growth in FY26, focusing on innovative medicines and increased R&D investment.